Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Average Rating of "Moderate Buy" by Brokerages

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six research firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $6.75.

A number of analysts recently weighed in on ESPR shares. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a report on Tuesday. Cantor Fitzgerald initiated coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 price objective on the stock. JMP Securities reaffirmed a "market outperform" rating and issued a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. Finally, The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a research note on Wednesday, December 18th. They issued a "neutral" rating and a $4.00 price objective on the stock.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Summit Financial LLC boosted its position in shares of Esperion Therapeutics by 18.2% during the fourth quarter. Summit Financial LLC now owns 46,528 shares of the biopharmaceutical company's stock worth $102,000 after purchasing an additional 7,150 shares in the last quarter. Foundations Investment Advisors LLC boosted its position in shares of Esperion Therapeutics by 48.6% during the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock worth $66,000 after purchasing an additional 9,872 shares in the last quarter. Invesco Ltd. raised its holdings in shares of Esperion Therapeutics by 15.5% during the fourth quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company's stock worth $215,000 after acquiring an additional 13,101 shares during the period. Two Sigma Advisers LP raised its holdings in shares of Esperion Therapeutics by 0.4% during the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock worth $7,956,000 after acquiring an additional 16,100 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in shares of Esperion Therapeutics by 15.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 123,896 shares of the biopharmaceutical company's stock worth $273,000 after acquiring an additional 16,404 shares during the period. 47.39% of the stock is owned by institutional investors.

Remove Ads

Esperion Therapeutics Price Performance

Shares of NASDAQ:ESPR traded down $0.07 during midday trading on Monday, reaching $1.59. The company's stock had a trading volume of 1,877,293 shares, compared to its average volume of 4,028,842. The business's fifty day simple moving average is $1.99 and its 200-day simple moving average is $2.09. Esperion Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $3.94. The company has a market capitalization of $312.30 million, a P/E ratio of -2.48 and a beta of 1.01.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.